Kaken Pharmaceutical Co., Ltd. (KKPCF) Comparison with companies in other sectors?

Kaken Pharmaceutical Co., Ltd. has a share price of 36.60M. You can analyze Kaken Pharmaceutical Co., Ltd. (KKPCF) competitors across different market sectors through stock heatmaps.

What are KKPCF's NET and operating margins?

Kaken Pharmaceutical Co., Ltd. (KKPCF) operating margin is around 0.22, and net profit margin is approximately 0.15 as of the latest reports.

In what way does KKPCF's earnings per share (EPS) trend reflect its financial momentum?

Kaken Pharmaceutical Co., Ltd. (KKPCF) EPS is 2.48 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Kaken Pharmaceutical Co., Ltd. is 11.33, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Kaken Pharmaceutical Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Kaken Pharmaceutical Co., Ltd. like P/E which is 11.60, P/B which is 1.06, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Kaken Pharmaceutical Co., Ltd.

KKPCF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$28.09

$0.00(0.00%)

Fundamental Analysis of Kaken Pharmaceutical Co., Ltd. (KKPCF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$2.48

P/E Ratio

11.33

ROE

0.09%

Net Margin

0.15%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.03B

Shares OutstandingTotal number of shares issued

$36.60M

Book Value/ShareNet worth per share

$3910.48

Revenue/ShareAnnual revenue per share

$2409.18

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.48

Net MarginNet income as percentage of revenue

14.83%

Operating MarginOperating income as percentage of revenue

22.37%

ROEReturn on shareholders' equity

9.22%

ROAReturn on total assets

7.32%

ROCEReturn on capital employed

13.14%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$1795.58

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$41.86

Dividend YieldAnnual dividend as percentage of stock price

1.010%

Financial Ratios Analysis data is not available for KKPCFFinancial Ratios Analysis details for KKPCF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for KKPCFSector Benchmarking details for KKPCF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Kaken Pharmaceutical Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Kaken Pharmaceutical Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Kaken Pharmaceutical Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Kaken Pharmaceutical Co., Ltd.

For Kaken Pharmaceutical Co., Ltd., essential financial indicators include EPS 2.48, PE 11.33, and ROE 0.09. These key ratios reveal insights into Kaken Pharmaceutical Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Kaken Pharmaceutical Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Kaken Pharmaceutical Co., Ltd.

Metrics like Net Margin 14.83% and ROA 7.32% shed light on how well Kaken Pharmaceutical Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Kaken Pharmaceutical Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Kaken Pharmaceutical Co., Ltd.

Using ratios such as P/B Ratio 1.06 and PEG Ratio -0.00, investors can assess whether Kaken Pharmaceutical Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Kaken Pharmaceutical Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Kaken Pharmaceutical Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow -, provide a snapshot of Kaken Pharmaceutical Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Kaken Pharmaceutical Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Kaken Pharmaceutical Co., Ltd.

Investing in Kaken Pharmaceutical Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Kaken Pharmaceutical Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;